Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Liabilities (2018 - 2025)

BioNexus Gene Lab's Total Liabilities history spans 8 years, with the latest figure at $637856.0 for Q4 2025.

  • Quarterly results put Total Liabilities at $637856.0 for Q4 2025, down 69.78% from a year ago — trailing twelve months through Dec 2025 was $637856.0 (down 69.78% YoY), and the annual figure for FY2025 was $637856.0, down 69.78%.
  • Total Liabilities for Q4 2025 was $637856.0 at BioNexus Gene Lab, down from $804966.0 in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $3.1 million in Q1 2021 to a low of $637856.0 in Q4 2025.
  • The 5-year median for Total Liabilities is $1.8 million (2023), against an average of $1.9 million.
  • The sharpest move saw Total Liabilities soared 3224.06% in 2021, then crashed 69.78% in 2025.
  • Year by year, Total Liabilities stood at $2.4 million in 2021, then decreased by 13.34% to $2.1 million in 2022, then fell by 16.06% to $1.7 million in 2023, then grew by 21.19% to $2.1 million in 2024, then crashed by 69.78% to $637856.0 in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $637856.0, $804966.0, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.